Anebulo Pharmaceuticals Reports Q1 2026 Financial Results
Anebulo Pharmaceuticals reported Q1 2026 financial results, with operating expenses of $2.3 million and a net loss of $2.2 million. The company has $10.4 million in cash reserves. Anebulo commenced a Phase 1 trial for its drug selonabant, targeting cannabis-induced toxicity in children, supported by a grant from the National Institute on Drug Abuse. The company is exploring strategic alternatives, including a potential reverse stock split, to address unmet needs in cannabis toxicity treatments.
Anebulo Pharmaceuticals, Inc. ( (ANEB) ) has released its Q1 earnings. Here is a breakdown of the information Anebulo Pharmaceuticals, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cannabis-induced toxicity, particularly in pediatric patients. In its recent earnings report, Anebulo highlighted the commencement of a Phase 1 clinical trial for an intravenous formulation of its lead drug candidate, selonabant, aimed at treating acute cannabis-induced toxicity in children. The company also received a significant grant from the National Institute on Drug Abuse to support this study. Financially, Anebulo reported operating expenses of $2.3 million and a net loss of $2.2 million for the first quarter of fiscal year 2026, with cash reserves of $10.4 million. Looking ahead, Anebulo is focused on advancing its selonabant IV formulation and exploring strategic alternatives, including a potential reverse stock split, as it aims to address the unmet need for treatments in cannabis toxicity, particularly in children.
